The large MRC/ECOG adult acute lymphoblastic leukemia (ALL) study establishes the value of sibling donor allogeneic transplant in standard-risk patients demonstrating superior outcome to conventional chemotherapy. The small but significant number of patients having matched unrelated donor (MUD) transplants on this study protocol appear to do well, and may establish the value of such an approach for those without a sibling. Reduced-intensity conditioning (RIC) conditioning might begin to address the transplant-related mortality problems of the older patients. The youngest adults may not need a transplant at all. If they are now treated on pediatric chemotherapy protocols, their outcome appears to improve significantly. The MRC/ECOG study, th...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, imm...
The large MRC/ECOG adult acute lymphoblastic leukemia (ALL) study establishes the value of sibling d...
An international collaboration was set up to prospectively evaluate the role of allogeneic transplan...
An international collaboration was set up to prospectively evaluate the role of allogeneic transplan...
An international collaboration was set up to prospectively evaluate the role of allogeneic transplan...
Until 10 to 15 years ago allogeneic transplants were performed in acute lymphoblastic leukemkia (ALL...
Background: Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-...
AbstractThe aim of the present study was to identify graft-versus-leukemia effects and the factors t...
Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strat...
AbstractDuring the last 10 years, multiple studies using reduced-intensity (RI) conditioning followe...
Acute lymphoblastic leukemia (ALL) with high-risk features has a poor prognosis in adults despite ag...
Background: Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, imm...
The large MRC/ECOG adult acute lymphoblastic leukemia (ALL) study establishes the value of sibling d...
An international collaboration was set up to prospectively evaluate the role of allogeneic transplan...
An international collaboration was set up to prospectively evaluate the role of allogeneic transplan...
An international collaboration was set up to prospectively evaluate the role of allogeneic transplan...
Until 10 to 15 years ago allogeneic transplants were performed in acute lymphoblastic leukemkia (ALL...
Background: Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-...
AbstractThe aim of the present study was to identify graft-versus-leukemia effects and the factors t...
Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strat...
AbstractDuring the last 10 years, multiple studies using reduced-intensity (RI) conditioning followe...
Acute lymphoblastic leukemia (ALL) with high-risk features has a poor prognosis in adults despite ag...
Background: Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hema...
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, imm...